90 citations
,
October 2023 in “Advanced Drug Delivery Reviews” This review highlights that unresolved inflammation is a major issue in diabetic foot ulcers and discusses emerging biomaterials-based strategies to modulate the inflammatory response, potentially aiding in tissue regeneration and healing in these chronic wounds.
56 citations
,
January 2023 in “Genes & Diseases” This study discusses a hypothesis for repurposing non-cancer drugs and combining micronutrients to target cancer and cancer stem cells with fewer side effects, suggesting a potential new approach for more effective cancer therapy.
March 2025 in “Health Science Reports” In this study, SLE was found to be more prevalent among Iraqi women, with photosensitivity, hair loss, and malar rash as common symptoms, contributing to the understanding of SLE patterns globally.
September 2024 in “Current Drug Delivery” This study found that Ginger-Derived Extracellular Vesicles (GDEVs) may promote hair growth and reduce inflammation in an alopecia mouse model.
51 citations
,
October 2024 in “Pharmaceutics” This review highlights the potential of permeation enhancers to improve the delivery of active ingredients across the skin, optimizing therapeutic outcomes despite challenges posed by individual variability and environmental factors, according to the authors' analysis of current understanding and applications in skincare and transdermal therapies.
42 citations
,
June 2021 in “Pharmaceutics” This review summarizes the use of 3D printing technologies for creating microneedles and evaluates their associated benefits, challenges, and regulatory considerations, but does not present new experimental results.
39 citations
,
April 2012 in “Journal of controlled release” This study found that using a protease-triggered release system enabled effective delivery of a model drug deep within porcine hair follicles, suggesting a new approach for treating skin conditions.
21 citations
,
June 2024 in “Pharmaceuticals” This review examines the potential of swellable microneedles in drug delivery and diagnostics, highlighting innovations and challenges in their use for chronic disease treatment, but noting that issues like physiological responsiveness and long-term stability still require research.
2 citations
,
December 2023 in “Advanced science” This review discusses the roles and mechanisms of glycosaminoglycans in wound healing and presents challenges and potential applications for GAG-based biomaterials without reporting new experimental results.
January 2025 in “AAPS PharmSciTech” Transethosomes improve drug delivery through the skin and show promise for treating various conditions.
March 2024 in “Journal of pharmacy & pharmaceutical sciences” This review discusses the design strategies and applications of long-acting polymeric microneedles, noting their potential to improve patient compliance and reduce side effects in chronic disease management, but reports no new experimental results.
15 citations
,
November 2024 in “Pharmaceutics” This review discusses how recent advancements in computational and lab-based methods have enhanced peptide drug discovery, noting the efficiency and cost benefits over traditional approaches and the potential for targeting difficult protein interactions, including protein degradation using proteolysis-targeting chimeras.
This research found that liposome drug delivery systems, particularly with targeted modifications, show promise for improving effectiveness and reducing toxicity in combination cancer therapies.
September 2024 in “Colloids and Surfaces B Biointerfaces” This study found that cedrol nanoemulsions significantly promote hair follicle regeneration and reduce DHT levels in an androgenic alopecia mouse model, suggesting potential efficacy in AGA treatment.
April 2023 in “IntechOpen eBooks” This article reviews drug repurposing as a strategy to overcome challenges in drug discovery, emphasizing AI and machine learning's role, but presents no new clinical results.
February 2020 in “Oncology Times” This article reviews antibody drug conjugates for cancer treatment, describing their mechanism, recent approvals, and ongoing research efforts, but reports no new clinical results.
24 citations
,
July 2023 in “Journal of Functional Biomaterials” This review evaluates recent advances from 2016 to 2022 in the use of microbubbles and nanobubbles, highlighting their potential for safer diagnostic and therapeutic applications in radiology and medicine without the side effects associated with traditional methods.
15 citations
,
June 2025 in “Journal of Extracellular Vesicles” This review examines various methods for purifying extracellular vesicles loaded with drugs, highlighting their principles, benefits, and drawbacks, and stresses the importance of standardized guidelines to enhance the reproducibility of EV-based drug delivery research.
4 citations
,
January 2022 in “Yonsei Medical Journal” This article discusses the potential of novel microneedle transdermal systems for enhanced drug and vaccine delivery through the skin, but reports no clinical results and emphasizes ongoing trials.
3 citations
,
August 2022 in “Pharmaceuticals” This study observed that a self-emulsifying drug delivery system for finasteride significantly enhanced bioavailability in rats compared to commercial tablets, but the formulation was found to be thermodynamically unstable.
2 citations
,
August 2023 in “Pharmaceutics” This paper reviews the development of transdermal drug delivery systems for skin diseases, from first to fourth generation, and highlights ongoing challenges and the importance of clinical trials, but provides no new clinical results.
2 citations
,
May 2023 in “Nanomaterials” This review explores the formulation, characterization, and applications of microemulsions, highlighting their potential for enhanced cutaneous drug delivery by improving bioavailability and enabling sustained release of both hydrophilic and hydrophobic drugs.
1 citations
,
July 2023 in “Pharmaceutics” In this study, researchers developed grooved microneedles made from hyaluronic acid for precise transdermal drug delivery, achieving accurate dosage with a high probability of delivery (98% or more) by using an easy-to-operate applicator for shearing force.
June 2026 in “International Journal of Drug Delivery Technology” This study developed EGCG-loaded nanohydrogels using ethyl cellulose and polyvinyl alcohol to enhance the stability and delivery of the hydrophilic drug in aloe vera gel, optimizing encapsulation efficiency and drug release properties.
2 citations
,
June 2024 in “JAAD reviews.” In this review, researchers summarize drugs associated with scarring or permanent hair loss, notably after chemotherapy and tyrosine kinase inhibitor treatments, emphasizing the need for stronger evidence and long-term follow-up studies, as current findings are mostly from case reports.
170 citations
,
September 2020 in “Viruses” This review highlights that drug repositioning offers a cost-effective alternative to traditional drug discovery, especially for treating orphan and resistant diseases like COVID-19, by repurposing existing drugs such as Hydroxychloroquine and Remdesivir.
1 citations
,
January 2020 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” This thesis explored how stratum corneum barrier disruption and pH-sensitive nanoparticles influence drug penetration and release in skin models, highlighting potential applications for treating atopic dermatitis.
June 2026 in “Pharmaceuticals” This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.
April 2026 in “Biomolecules” This review highlights recent advancements in molecular understanding and treatment approaches for PCOS, including innovative drug delivery systems and AI-driven precision medicine, but provides no new clinical results.
April 2026 in “Therapeutic Advances in Drug Safety” This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.